Peng Luo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6326757/publications.pdf

Version: 2024-02-01

76 papers	1,569 citations	331670 21 h-index	377865 34 g-index
84 all docs	84 docs citations	84 times ranked	1510 citing authors

#	Article	IF	Citations
1	Application of ATAC-seq in tumor-specific T cell exhaustion. Cancer Gene Therapy, 2023, 30, 1-10.	4.6	4
2	Survival Analysis of TP53 Comutations Should Be Interpreted More Cautiously. Journal of Thoracic Oncology, 2022, 17, e14-e18.	1.1	3
3	MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 757137.	3.7	13
4	Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response. Frontiers in Immunology, 2022, 13, 833792.	4.8	5
5	Targeting papain-like protease for broad-spectrum coronavirus inhibition. Protein and Cell, 2022, 13, 940-953.	11.0	23
6	Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer. Frontiers in Immunology, 2022, 13, 810471.	4.8	16
7	CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer. Briefings in Bioinformatics, 2022, 23, .	6.5	52
8	Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. , 2022, 19, 588-601.		27
9	Identify the Prognostic and Immune Profile of VSIR in the Tumor Microenvironment: A Pan-Cancer Analysis. Frontiers in Cell and Developmental Biology, 2022, 10, 821649.	3.7	4
10	The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma. Frontiers in Immunology, 2022, 13, 749241.	4.8	15
11	Genomic and immunological profiles of small-cell lung cancer between East Asians and Caucasian. Cancer Cell International, 2022, 22, 173.	4.1	6
12	Deep Learning Analysis of the Adipose Tissue and the Prediction of Prognosis in Colorectal Cancer. Frontiers in Nutrition, 2022, 9, .	3.7	5
13	Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma. Cancer Cell International, 2022, 22, 186.	4.1	4
14	UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer. Bioengineered, 2022, 13, 11577-11592.	3.2	6
15	Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment. Journal of Immunology Research, 2022, 2022, 1-14.	2.2	4
16	A Novel Thrombosis-Related Signature for Predicting Survival and Drug Compounds in Glioblastoma. Journal of Oncology, 2022, 2022, 1-16.	1.3	1
17	Relationship between ATOH1 and tumor microenvironment in colon adenocarcinoma patients with different microsatellite instability status. Cancer Cell International, 2022, 22, .	4.1	3
18	EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma. Cancer Gene Therapy, 2021, 28, 864-874.	4.6	27

#	Article	IF	Citations
19	ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2021, 70, 137-151.	4.2	69
20	Identification of a novel CpG methylation signature to predict prognosis in lung squamous cell carcinoma. Cancer Biomarkers, 2021, 30, 63-73.	1.7	6
21	Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer. Frontiers in Immunology, 2021, 12, 630773.	4.8	22
22	Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma. Frontiers in Molecular Biosciences, 2021, 8, 629330.	3.5	3
23	Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 2021, 12, 645862.	3.5	7
24	Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration. Frontiers in Oncology, 2021, 11, 670927.	2.8	9
25	Activation of the DDR Pathway Leads to the Down-Regulation of the TGFÎ² Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma. Frontiers in Immunology, 2021, 12, 634741.	4.8	20
26	Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma. Frontiers in Pharmacology, 2021, 12, 723066.	3.5	1
27	High mutations in fatty acid metabolism contribute to a better prognosis of smallâ€cell lung cancer patients treated with chemotherapy. Cancer Medicine, 2021, 10, 7863-7876.	2.8	3
28	Applications of Machine Learning to Predict Cisplatin Resistance in Lung Cancer. International Journal of General Medicine, 2021, Volume 14, 5911-5925.	1.8	9
29	TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 667875.	4.8	11
30	Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. Annals of Translational Medicine, 2021, 9, 1475-1475.	1.7	3
31	The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 745859.	3.7	14
32	Severe fever with thrombocytopenia syndrome virus (SFTSV)-host interactome screen identifies viral nucleoprotein-associated host factors as potential antiviral targets. Computational and Structural Biotechnology Journal, 2021, 19, 5568-5577.	4.1	3
33	Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma. Frontiers in Pharmacology, 2021, 12, 721181.	3.5	5
34	Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes. Frontiers in Immunology, 2021, 12, 756722.	4.8	35
35	CARD11 alteration as a candidate biomarker of skin cutaneous melanoma treated with immune checkpoint blockade. American Journal of Translational Research (discontinued), 2021, 13, 286-300.	0.0	4
36	Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 762478.	3.7	8

#	Article	IF	Citations
37	CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 770811.	3.7	4
38	Comparison of the incidence of colorectal cancer in young adults between the USA and Europe. Gut, 2020, 69, 1540-1542.	12.1	3
39	Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 608969.	3.7	29
40	A comparison of the efficacy of antiangiogenic agents combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis. Cancer Cell International, 2020, 20, 548.	4.1	3
41	Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Frontiers in Immunology, 2020, 11, 2039.	4.8	187
42	ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment. Frontiers in Genetics, 2020, 11, 933.	2.3	32
43	PrognosisÂof Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 2020, 11, 1213.	3.5	28
44	Current status, challenges and perspectives: immunotherapy and tumour microenvironment in thoracic cancer. Journal of Thoracic Disease, 2020, 12, 4496-4497.	1.4	0
45	Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma. Biomedicine and Pharmacotherapy, 2020, 131, 110633.	5.6	6
46	Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer. Pharmacological Research, 2020, 159, 105028.	7.1	45
47	Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis. Journal of Cancer, 2020, 11, 1816-1827.	2.5	5
48	Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition. Cancer Control, 2020, 27, 107327482097666.	1.8	25
49	DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer. Aging, 2020, 12, 1285-1303.	3.1	25
50	CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter. Theranostics, 2019, 9, 4717-4729.	10.0	45
51	A novel mutation panel for predicting etoposide resistance in small-cell lung cancer . Drug Design, Development and Therapy, 2019, Volume 13, 2021-2041.	4.3	50
52	Immune Cell Infiltration Is a Strong Prognostic Indicator in Surgical Resection of SCLC. Journal of Thoracic Oncology, 2019, 14, e242-e243.	1.1	5
53	Association between Circulating Inflammatory Proteins and Clinical Prognosis in Chinese Patients with EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, e222-e224.	1.1	3
54	Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Molecular Cancer, 2019, 18, 139.	19.2	156

#	Article	IF	Citations
55	The efficacy of the new medical internship management network system. Medicine (United States), 2019, 98, e14435.	1.0	7
56	Reply to: Osimertinib and jaw osteonecrosis? A case report. International Journal of Cancer, 2019, 145, 2006-2007.	5.1	0
57	Identification of aberrantly methylated differentially expressed genes in breast cancer by integrated bioinformatics analysis. Journal of Cellular Biochemistry, 2019, 120, 16229-16243.	2.6	5
58	DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing. Journal of Thoracic Oncology, 2019, 14, e276-e279.	1.1	27
59	Efficacy and safety of osimertinib in treating EGFRâ€mutated advanced NSCLC: A metaâ€analysis. International Journal of Cancer, 2019, 145, 284-294.	5.1	52
60	Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis. Expert Review of Gastroenterology and Hepatology, 2019, 13, 271-279.	3.0	8
61	Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis. Gynecologic Oncology, 2018, 149, 612-619.	1.4	14
62	Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis. Journal of Cancer, 2018, 9, 4556-4567.	2.5	9
63	The efficacy and safety of <scp>ALK</scp> inhibitors in the treatment of <scp>ALK</scp>â€positive nonâ€small cell lung cancer: A network metaâ€analysis. Cancer Medicine, 2018, 7, 4993-5005.	2.8	31
64	Glia maturation factor-β: a potential therapeutic target in neurodegeneration and neuroinflammation. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 495-504.	2.2	33
65	The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 1105-1115.	2.0	16
66	Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap. Drug Design, Development and Therapy, 2018, Volume 12, 2371-2379.	4.3	20
67	Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer. Drug Design, Development and Therapy, 2018, Volume 12, 2455-2466.	4.3	18
68	The Relationship between Neutrophil-to-Lymphocyte Ratio and Intracerebral Hemorrhage in Type 2 Diabetes Mellitus. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 930-937.	1.6	11
69	Kennedy disease with difficulty in differential diagnosis. Medicine (United States), 2017, 96, e6792.	1.0	0
70	The relationship between neutrophil-to-lymphocyte ratio and diabetic peripheral neuropathy in Type 2 diabetes mellitus. Medicine (United States), 2017, 96, e8289.	1.0	48
71	Continuous intrathecal administration of liposomal amphotericin B for treatment of refractory Cryptococcus neoformans encephalitis: A case report. Experimental and Therapeutic Medicine, 2017, 14, 780-784.	1.8	8
72	The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor. Cancer Management and Research, 2017, Volume 9, 801-811.	1.9	14

#	Article	IF	Citations
73	The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer. Drug Design, Development and Therapy, 2017, Volume 11, 3367-3376.	4.3	6
74	Efficiency and safety of roflumilast combined with long-acting bronchodilators on moderate-to-severe stable chronic obstructive pulmonary disease patients: a meta-analysis. Journal of Thoracic Disease, 2016, 8, 2638-2645.	1.4	7
75	Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients. BMC Endocrine Disorders, 2015, 15, 9.	2.2	116
76	THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients. Drug Design, Development and Therapy, 0, Volume 16, 1679-1695.	4.3	5